002020 京新药业
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入3,208,7449.68%3,998,8353,779,8463,466,5503,258,075
减:营业总成本2,608,1107.19%3,367,0363,084,8492,841,5132,739,989
    其中:营业成本1,568,8319.43%1,976,4881,766,1491,543,6591,273,328
               财务费用(46,572)21.80%(53,828)(72,321)(37,581)(2,612)
               资产减值损失102-93.14%(21,145)(20,898)(10,271)(2,233)
公允价值变动收益894-33.18%36,77123,9527,233131,493
投资收益5,970-10.30%6,44119,41648,15859,662
    其中:对联营企业和合营企业的投资收益----(6,042)(4,165)(4,252)(6,235)
营业利润671,81525.46%714,059756,616698,053765,386
利润总额676,46426.18%708,041750,316699,536758,979
减:所得税费用95,90559.47%84,62382,49381,572105,652
净利润580,55921.98%623,418667,823617,963653,327
减:非控股权益5,54766.63%4,5205,5695,422257
股东净利润575,01321.66%618,898662,254612,542653,070

市场价值指针
每股收益 (元) *0.67021.82%0.7200.7700.7500.820
每股派息 (元) *----0.3000.3000.3000.350
每股净资产 (元) *6.7708.73%6.4025.9775.3215.553
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容